Syros Net Working Capital vs Current Deferred Revenue Analysis

SYRS Stock

USD 5.10 0.10 2.00%

Syros Pharmaceuticals financial indicator trend analysis is much more than just breaking down Syros Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Syros Pharmaceuticals is a good investment. Please check the relationship between Syros Pharmaceuticals Net Working Capital and its Current Deferred Revenue accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syros Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Syros Stock please use our How to Invest in Syros Pharmaceuticals guide.

Net Working Capital vs Current Deferred Revenue

Net Working Capital vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Syros Pharmaceuticals Net Working Capital account and Current Deferred Revenue. At this time, the significance of the direction appears to have strong relationship.

The correlation between Syros Pharmaceuticals' Net Working Capital and Current Deferred Revenue is 0.73. Overlapping area represents the amount of variation of Net Working Capital that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Syros Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Syros Pharmaceuticals' Net Working Capital and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Working Capital of Syros Pharmaceuticals are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Net Working Capital i.e., Syros Pharmaceuticals' Net Working Capital and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.73

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Net Working Capital

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Syros Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Syros Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syros Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Syros Stock please use our How to Invest in Syros Pharmaceuticals guide.Issuance Of Capital Stock is likely to gain to about 86.2 M in 2024, whereas Selling General Administrative is likely to drop slightly above 18.9 M in 2024.

Syros Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab	Property Plant And Equipment Gross
Total Assets		0.85	0.91	0.44	0.81	0.85	0.9	-0.47	-0.83	0.56	0.84	0.89	0.71	0.81	0.88	0.97	0.03	0.69	0.55	-0.16	0.85	0.88	0.92	0.86	0.18	0.94
Other Current Liab	0.85		0.95	0.27	0.69	0.9	0.74	-0.18	-0.85	0.66	0.57	0.76	0.72	0.58	0.87	0.83	0.35	0.7	0.61	0.05	0.74	0.85	0.94	0.79	-0.18	0.8
Total Current Liabilities	0.91	0.95		0.18	0.8	0.9	0.87	-0.24	-0.91	0.72	0.68	0.87	0.69	0.74	0.91	0.86	0.19	0.72	0.66	-0.14	0.86	0.86	0.98	0.89	0.06	0.91
Total Stockholder Equity	0.44	0.27	0.18		-0.01	0.1	0.31	-0.13	0.08	-0.41	0.28	0.33	0.37	0.2	0.35	0.45	0.2	0.28	-0.43	0.53	-0.08	0.28	0.21	-0.06	0.07	0.33
Other Liab	0.81	0.69	0.8	-0.01		0.83	0.78	-0.53	-0.85	0.81	0.73	0.68	0.33	0.77	0.75	0.79	0.07	0.72	0.76	-0.43	0.91	0.74	0.79	0.91	0.09	0.75
Net Tangible Assets	0.85	0.9	0.9	0.1	0.83		0.73	-0.39	-0.93	0.77	0.66	0.72	0.56	0.65	0.76	0.85	0.15	0.74	0.79	-0.28	0.88	0.8	0.9	0.9	-0.2	0.77
Property Plant And Equipment Net	0.9	0.74	0.87	0.31	0.78	0.73		-0.16	-0.75	0.56	0.63	0.97	0.61	0.76	0.86	0.78	0.14	0.73	0.45	-0.09	0.8	0.73	0.83	0.81	0.36	0.97
Net Debt	-0.47	-0.18	-0.24	-0.13	-0.53	-0.39	-0.16		0.39	-0.26	-0.82	-0.11	-0.13	-0.59	-0.2	-0.62	0.52	-0.16	-0.41	0.67	-0.51	-0.41	-0.33	-0.46	-0.08	-0.21
Retained Earnings	-0.83	-0.85	-0.91	0.08	-0.85	-0.93	-0.75	0.39		-0.89	-0.7	-0.75	-0.63	-0.65	-0.76	-0.81	0.01	-0.55	-0.9	0.37	-0.96	-0.86	-0.92	-0.97	-0.01	-0.82
Accounts Payable	0.56	0.66	0.72	-0.41	0.81	0.77	0.56	-0.26	-0.89		0.45	0.52	0.39	0.45	0.54	0.52	-0.01	0.41	0.94	-0.44	0.85	0.7	0.71	0.86	0.01	0.6
Cash	0.84	0.57	0.68	0.28	0.73	0.66	0.63	-0.82	-0.7	0.45		0.62	0.52	0.86	0.61	0.9	-0.38	0.42	0.53	-0.54	0.79	0.75	0.74	0.77	0.3	0.7
Non Current Assets Total	0.89	0.76	0.87	0.33	0.68	0.72	0.97	-0.11	-0.75	0.52	0.62		0.75	0.71	0.85	0.78	0.08	0.65	0.44	-0.04	0.78	0.74	0.83	0.8	0.36	0.98
Non Currrent Assets Other	0.71	0.72	0.69	0.37	0.33	0.56	0.61	-0.13	-0.63	0.39	0.52	0.75		0.45	0.59	0.68	-0.1	0.26	0.35	0.06	0.56	0.71	0.69	0.59	0.23	0.74
Other Assets	0.81	0.58	0.74	0.2	0.77	0.65	0.76	-0.59	-0.65	0.45	0.86	0.71	0.45		0.67	0.81	-0.12	0.7	0.42	-0.51	0.77	0.58	0.71	0.77	0.3	0.73
Long Term Debt	0.88	0.87	0.91	0.35	0.75	0.76	0.86	-0.2	-0.76	0.54	0.61	0.85	0.59	0.67		0.82	0.31	0.74	0.47	0.07	0.74	0.76	0.88	0.77	0.03	0.86
Cash And Short Term Investments	0.97	0.83	0.86	0.45	0.79	0.85	0.78	-0.62	-0.81	0.52	0.9	0.78	0.68	0.81	0.82		-0.04	0.64	0.56	-0.24	0.82	0.87	0.9	0.83	0.09	0.84
Net Receivables	0.03	0.35	0.19	0.2	0.07	0.15	0.14	0.52	0.01	-0.01	-0.38	0.08	-0.1	-0.12	0.31	-0.04		0.51	-0.13	0.66	-0.14	-0.01	0.14	-0.07	-0.55	0.05
Common Stock Total Equity	0.69	0.7	0.72	0.28	0.72	0.74	0.73	-0.16	-0.55	0.41	0.42	0.65	0.26	0.7	0.74	0.64	0.51		0.31	-0.04	0.58	0.42	0.63	0.61	-0.22	0.62
Common Stock Shares Outstanding	0.55	0.61	0.66	-0.43	0.76	0.79	0.45	-0.41	-0.9	0.94	0.53	0.44	0.35	0.42	0.47	0.56	-0.13	0.31		-0.55	0.86	0.68	0.7	0.86	-0.09	0.53
Short Term Investments	-0.16	0.05	-0.14	0.53	-0.43	-0.28	-0.09	0.67	0.37	-0.44	-0.54	-0.04	0.06	-0.51	0.07	-0.24	0.66	-0.04	-0.55		-0.53	-0.11	-0.15	-0.47	-0.23	-0.09
Non Current Liabilities Total	0.85	0.74	0.86	-0.08	0.91	0.88	0.8	-0.51	-0.96	0.85	0.79	0.78	0.56	0.77	0.74	0.82	-0.14	0.58	0.86	-0.53		0.8	0.87	1.0	0.16	0.83
Other Current Assets	0.88	0.85	0.86	0.28	0.74	0.8	0.73	-0.41	-0.86	0.7	0.75	0.74	0.71	0.58	0.76	0.87	-0.01	0.42	0.68	-0.11	0.8		0.93	0.81	0.18	0.85
Other Stockholder Equity	0.92	0.94	0.98	0.21	0.79	0.9	0.83	-0.33	-0.92	0.71	0.74	0.83	0.69	0.71	0.88	0.9	0.14	0.63	0.7	-0.15	0.87	0.93		0.89	0.07	0.9
Total Liab	0.86	0.79	0.89	-0.06	0.91	0.9	0.81	-0.46	-0.97	0.86	0.77	0.8	0.59	0.77	0.77	0.83	-0.07	0.61	0.86	-0.47	1.0	0.81	0.89		0.12	0.85
Deferred Long Term Liab	0.18	-0.18	0.06	0.07	0.09	-0.2	0.36	-0.08	-0.01	0.01	0.3	0.36	0.23	0.3	0.03	0.09	-0.55	-0.22	-0.09	-0.23	0.16	0.18	0.07	0.12		0.36
Property Plant And Equipment Gross	0.94	0.8	0.91	0.33	0.75	0.77	0.97	-0.21	-0.82	0.6	0.7	0.98	0.74	0.73	0.86	0.84	0.05	0.62	0.53	-0.09	0.83	0.85	0.9	0.85	0.36

Click cells to compare fundamentals

Syros Pharmaceuticals Account Relationship Matchups

Syros Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	150.0M	213.3M	182.9M	244.5M	168.2M	147.5M
Other Current Liab	10.6M	11.1M	15.6M	18.0M	16.1M	11.6M
Total Current Liabilities	23.5M	28.6M	31.5M	30.8M	36.7M	22.2M
Total Stockholder Equity	79.2M	90.6M	85.2M	127.7M	16.7M	15.8M
Other Liab	22.6M	29.6M	3.0M	24.5M	28.1M	29.5M
Net Tangible Assets	79.2M	125.4M	106.1M	148.6M	170.9M	179.4M
Property Plant And Equipment Net	31.9M	29.6M	27.3M	24.7M	19.5M	16.6M
Net Debt	(15.5M)	(107.8M)	(27.1M)	(103.9M)	(77.5M)	(81.3M)
Retained Earnings	(293.0M)	(377.0M)	(463.6M)	(558.2M)	(722.8M)	(686.7M)
Accounts Payable	5.9M	3.6M	3.7M	6.4M	11.5M	12.1M
Cash	41.4M	174.0M	92.3M	167.5M	139.5M	93.7M
Non Current Assets Total	35.5M	34.7M	46.4M	33.1M	23.2M	21.7M
Non Currrent Assets Other	490K	2.0M	6.0M	5.3M	1.6M	2.4M
Other Assets	3.6M	20.5M	6.0M	8.4M	9.7M	5.4M
Cash And Short Term Investments	91.4M	174.0M	130.4M	202.3M	139.5M	119.8M
Common Stock Total Equity	26K	34K	43K	56K	20K	28.2K
Common Stock Shares Outstanding	4.0M	4.6M	6.3M	12.6M	28.3M	29.7M
Short Term Investments	39.8M	49.8M	50.0M	0.0	38.1M	34.8M
Liabilities And Stockholders Equity	150.0M	213.3M	182.9M	244.5M	168.2M	147.5M
Non Current Liabilities Total	47.3M	94.1M	66.2M	86.0M	114.8M	120.6M
Other Current Assets	2.6M	2.2M	3.2M	7.4M	5.5M	2.8M
Other Stockholder Equity	372.1M	467.5M	548.8M	685.8M	739.4M	377.3M
Total Liab	70.8M	122.7M	97.7M	116.8M	151.5M	159.1M
Property Plant And Equipment Gross	31.9M	29.6M	37.1M	37.2M	27.1M	19.9M
Total Current Assets	114.5M	178.6M	136.6M	211.4M	145.0M	125.8M
Accumulated Other Comprehensive Income	24K	0.0	(79K)	102K	117.3K	123.2K
Short Term Debt	1.3M	1.7M	2.0M	2.1M	9.0M	9.4M
Common Stock	34K	43K	56K	61K	20K	32.1K
Property Plant Equipment	31.9M	14.2M	27.3M	11.4M	13.1M	12.6M
Short Long Term Debt Total	25.9M	66.2M	65.2M	63.6M	62.1M	34.7M
Long Term Debt Total	22K	621K	39.6M	40.6M	46.7M	49.1M
Capital Surpluse	296.1M	372.1M	467.5M	685.8M	788.7M	828.2M
Current Deferred Revenue	5.7M	12.2M	10.2M	4.3M	5.0M	6.4M
Retained Earnings Total Equity	(217.5M)	(293.0M)	(377.0M)	(558.2M)	(502.4M)	(477.3M)
Capital Lease Obligations	25.9M	26.7M	24.9M	22.9M	20.9M	16.7M

Pair Trading with Syros Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Syros Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Syros Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Syros Stock

0.68

Equillium

Pair Corr

Moving against Syros Stock

0.54	VALN	Valneva SE ADR	Pair Corr
0.5	DOMH	Dominari Holdings	Pair Corr
0.46	VBIV	VBI Vaccines	Pair Corr
0.44	VCEL	Vericel Corp Ord	Pair Corr

The ability to find closely correlated positions to Syros Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Syros Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Syros Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Syros Pharmaceuticals to buy it.

The correlation of Syros Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Syros Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Syros Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Syros Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Syros Pharmaceuticals is a strong investment it is important to analyze Syros Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Syros Pharmaceuticals' future performance. For an informed investment choice regarding Syros Stock, refer to the following important reports:

How To Invest In Syros

Details

Is Syros Stock a good investment?

Details

What is Syros Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syros Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Syros Stock please use our How to Invest in Syros Pharmaceuticals guide.

You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for Syros Stock analysis

When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Stocks Directory Find actively traded stocks across global markets
	Commodity Directory Find actively traded commodities issued by global exchanges
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Fundamental Analysis View fundamental data based on most recent published financial statements
	Share Portfolio Track or share privately all of your investments from the convenience of any device

Is Syros Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Syros Pharmaceuticals. If investors know Syros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Syros Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(5.06)

Revenue Per Share

0.224

Quarterly Revenue Growth

(0.03)

Return On Assets

(0.46)

Return On Equity

(2.37)

The market value of Syros Pharmaceuticals is measured differently than its book value, which is the value of Syros that is recorded on the company's balance sheet. Investors also form their own opinion of Syros Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Syros Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Syros Pharmaceuticals' market value can be influenced by many factors that don't directly affect Syros Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Syros Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Syros Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Syros Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Syros Net Working Capital vs Current Deferred Revenue Analysis

Net Working Capital vs Current Deferred Revenue

Net Working Capital vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Net Working Capital

Current Deferred Revenue

Syros Pharmaceuticals fundamental ratios Correlations

Syros Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Syros Pharmaceuticals fundamental ratios Accounts

Pair Trading with Syros Pharmaceuticals

Moving together with Syros Stock

Moving against Syros Stock

Complementary Tools for Syros Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Non Current Liabilities Total
Other Stockholder Equity	+ 0.98	Total Current Liabilities
Property Plant And Equipment Gross	+ 0.98	Non Current Assets Total
Cash And Short Term Investments	+ 0.97	Total Assets
Non Current Assets Total	+ 0.97	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 0.97	Property Plant And Equipment Net

Total Liab	- 0.97	Retained Earnings
Non Current Liabilities Total	- 0.96	Retained Earnings
Retained Earnings	- 0.93	Net Tangible Assets
Other Stockholder Equity	- 0.92	Retained Earnings
Retained Earnings	- 0.91	Total Current Liabilities
Common Stock Shares Outstanding	- 0.9	Retained Earnings